Research programme: hepatitis C therapeutics - Enanta/Novartis
Alternative Names: HCV NS3 protein inhibitors - Enanta; Hepatitis C protease inhibitors - Novartis/EnantaLatest Information Update: 07 Oct 2014
At a glance
- Originator Enanta Pharmaceuticals; Novartis
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Hepatitis C protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 01 Oct 2014 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
- 05 May 2008 Development in this programme is ongoing
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis